+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Increased cerebrospinal fluid complement C5 levels in major depressive disorder and schizophrenia



Increased cerebrospinal fluid complement C5 levels in major depressive disorder and schizophrenia



Biochemical and Biophysical Research Communications 497(2): 683-688



Inflammation has been implicated in a variety of psychiatric disorders. We aimed to determine whether levels of complement C5 protein in the cerebrospinal fluid (CSF), which may reflect activation of the complement system in the brain, are altered in patients with major psychiatric disorders. Additionally, we examined possible associations of CSF C5 levels with clinical variables. Subjects comprised 89 patients with major depressive disorder (MDD), 66 patients with bipolar disorder (BPD), 96 patients with schizophrenia, and 117 healthy controls, matched for age, sex, and ethnicity (Japanese). Diagnosis was made according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, criteria. CSF C5 levels were measured by enzyme-linked immunosorbent assay. CSF C5 levels were significantly increased in the patients with MDD (p < 0.001) and in the patients with schizophrenia (p = 0.001), compared with the healthy controls. The rate of individuals with an "abnormally high C5 level" (i.e., above the 95th percentile value of the control subjects) was significantly increased in all psychiatric groups, relative to the control group (all p < 0.01). Older age, male sex, and greater body mass index tended to associate with higher C5 levels. There was a significantly positive correlation between C5 levels and chlorpromazine-equivalent dose in the patients with schizophrenia. Thus, we found, for the first time, elevated C5 levels in the CSF of patients with major psychiatric disorders. Our results suggest that the activated complement system may contribute to neurological pathogenesis in a portion of patients with major psychiatric disorders.

(PDF emailed within 0-6 h: $19.90)

Accession: 065232178

Download citation: RISBibTeXText

PMID: 29454970

DOI: 10.1016/j.bbrc.2018.02.131


Related references

Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. Journal of Psychiatric Research 47(3): 401-406, 2014

Plasma and cerebrospinal fluid G72 protein levels in schizophrenia and major depressive disorder. Psychiatry Research 254: 244-250, 2017

Cerebrospinal fluid BDNF pro-peptide levels in major depressive disorder and schizophrenia. Journal of Psychiatric Research 113: 190-198, 2019

Cerebrospinal fluid neural cell adhesion molecule levels and their correlation with clinical variables in patients with schizophrenia, bipolar disorder, and major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 76: 12-18, 2017

Increased cerebrospinal fluid fibrinogen levels in major depressive disorder replicated in a larger sample set. European Neuropsychopharmacology 26: S403-S404, 2016

Reduced Serum and Cerebrospinal Fluid Levels of Autotaxin in Major Depressive Disorder. International Journal of Neuropsychopharmacology 22(4): 261-269, 2019

Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. European Neuropsychopharmacology 17(9): 573-579, 2007

Relationships of Cerebrospinal Fluid Monoamine Metabolite Levels With Clinical Variables in Major Depressive Disorder. Journal of Clinical Psychiatry 78(8): E947-E956, 2017

Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE), but not S100B in major depressive disorder. World Journal of Biological Psychiatry 16(2): 106-113, 2015

Increased concentration of calcitonin gene-related peptide in cerebrospinal fluid of depressed patients. A possible trait marker of major depressive disorder. Neuroscience Letters 182(2): 138-142, 1994

Low cocaine- and amphetamine-regulated transcript (CART) peptide levels in human cerebrospinal fluid of major depressive disorder (MDD) patients. Journal of Affective Disorders 232: 134-138, 2018

Differential melatonin alterations in cerebrospinal fluid and serum of patients with major depressive disorder and bipolar disorder. Comprehensive Psychiatry 68: 34-39, 2017

Increased neuron numbers in the anterior thalamus in major depressive disorder, but not in bipolar disorder or schizophrenia. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 497 17, 2002

Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkers. Arquivos de Neuro-Psiquiatria 71(9b): 689-692, 2014

Hippocampal α7 nicotinic acetylcholine receptor levels in patients with schizophrenia, bipolar disorder, or major depressive disorder. Bipolar Disorders 13(7-8): 701-707, 2012